# IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study

> **NCT05417269** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Imcyse SA** · enrollment: 150 (estimated)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** IMCY-0141
- **DRUG:** Placebo
- **DRUG:** Dimethyl Fumarate

## Key facts

- **NCT ID:** NCT05417269
- **Lead sponsor:** Imcyse SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-12
- **Primary completion:** 2025-05-23
- **Final completion:** 2025-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417269, "IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05417269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*